Myria Biosciences combines artificial intelligence with synthetic biology to design microbial strains that synthesize therapeutic molecules. Their platform accelerates drug discovery by generating high‑performance microbes for unmet medical needs. The company delivers rapid, data‑driven analytics to streamline candidate selection and development.
Funding
Funding not disclosed
Founders
Product
Problem
Existing treatments have failed to address unmet medical needs in many diseases. Traditional drug discovery methods often struggle to produce effective drug candidates for these complex conditions.
Solution
Myria Biosciences develops Genetically Engineered Modular Molecule Scaffolds (GEMMS), a novel class of therapeutic molecules that combines the properties of small molecules and biologics. By integrating computational data mining, synthetic biology, and high-throughput experimentation, Myria generates and tests millions of molecules. This approach aims to create effective drug candidates for diseases where existing treatments are inadequate. The company leverages AI-designed microbes to produce therapies for these unmet medical needs.
Target Audience
Myria Biosciences targets pharmaceutical companies and research institutions focused on developing novel therapies for diseases with unmet medical needs.
Features
- GEMMS: A novel class of therapeutic molecules integrating small molecule and biologic properties.
- Computational data mining for molecule design and optimization.
- Synthetic biology techniques for molecule generation.
- High-throughput experimentation for rapid molecule testing and validation.
- AI-driven approach to identify and develop promising drug candidates.